XML 44 R33.htm IDEA: XBRL DOCUMENT v3.19.2
Fair Value Measurements (Details) - USD ($)
Jun. 30, 2019
Dec. 31, 2018
Jun. 30, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Cash equivalents $ 536,900,000 $ 266,000,000.0  
Debt securities, available-for-sale 668,300,000 210,600,000  
Transfers between Level 1 and Level 2 securities 0   $ 0
Transfers into or out of Level 3 securities 0   $ 0
Fair Value, Inputs, Level 1      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Cash equivalents 410,700,000 199,300,000  
Debt securities, available-for-sale 0 0  
Fair Value, Inputs, Level 2      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Cash equivalents 126,200,000 66,700,000  
Debt securities, available-for-sale 668,300,000 210,600,000  
Fair Value, Inputs, Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Cash equivalents 0 0  
Debt securities, available-for-sale 0 0  
U.S. government agencies      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Debt securities, available-for-sale 531,600,000 173,100,000  
U.S. government agencies | Fair Value, Inputs, Level 1      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Debt securities, available-for-sale 0 0  
U.S. government agencies | Fair Value, Inputs, Level 2      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Debt securities, available-for-sale 531,600,000 173,100,000  
U.S. government agencies | Fair Value, Inputs, Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Debt securities, available-for-sale 0 0  
Corporate debt      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Debt securities, available-for-sale 37,800,000 1,300,000  
Corporate debt | Fair Value, Inputs, Level 1      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Debt securities, available-for-sale 0 0  
Corporate debt | Fair Value, Inputs, Level 2      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Debt securities, available-for-sale 37,800,000 1,300,000  
Corporate debt | Fair Value, Inputs, Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Debt securities, available-for-sale 0 0  
Commercial paper      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Debt securities, available-for-sale 98,900,000 36,200,000  
Commercial paper | Fair Value, Inputs, Level 1      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Debt securities, available-for-sale 0 0  
Commercial paper | Fair Value, Inputs, Level 2      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Debt securities, available-for-sale 98,900,000 36,200,000  
Commercial paper | Fair Value, Inputs, Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Debt securities, available-for-sale 0 0  
Equity investment in Tandem Diabetes Care, Inc      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Equity investment in Tandem Diabetes Care, Inc.   38,000,000.0  
Equity investment in Tandem Diabetes Care, Inc | Fair Value, Inputs, Level 1      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Equity investment in Tandem Diabetes Care, Inc.   38,000,000.0  
Equity investment in Tandem Diabetes Care, Inc | Fair Value, Inputs, Level 2      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Equity investment in Tandem Diabetes Care, Inc.   0  
Equity investment in Tandem Diabetes Care, Inc | Fair Value, Inputs, Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Equity investment in Tandem Diabetes Care, Inc.   0  
Senior Notes      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Fair value of outstanding senior convertible notes: 1,635,200,000 1,399,800,000  
Senior convertible notes due 2022 | Senior Notes      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Fair value of outstanding senior convertible notes: 638,300,000 540,200,000  
Senior convertible notes due 2023 | Senior Notes      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Fair value of outstanding senior convertible notes: 996,900,000 859,600,000  
Foreign Exchange Forward | Designated as Hedging Instrument      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Outstanding currency hedging transactions 0    
Fair Value, Measurements, Recurring      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Total assets measured at fair value on a recurring basis 1,205,200,000 514,600,000  
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 1      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Total assets measured at fair value on a recurring basis 410,700,000 237,300,000  
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Total assets measured at fair value on a recurring basis 794,500,000 277,300,000  
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Total assets measured at fair value on a recurring basis $ 0 $ 0